Determination of pentosidine in urine and joint compartment tissues of patients with advanced osteoarthritis
Authors:
M. Braun; M. Adam; K. Pavelka; L. Šenolt
Authors‘ workplace:
Revmatologický ústav, Praha
Published in:
Čes. Revmatol., 15, 2007, No. 2, p. 59-63.
Category:
Original Papers
Overview
Objective:
Non-enzymatic glycation in vivo contributes to formation of advanced glycation end products which cause undesirable irreversible connective tissue changes as a result of cross-linkage. Determination of pentosidine, representative of such compounds, enable quantitative monitoring of degradation changes in osteoarthritic joints associated with inflammation and increased glycoxidation loading of the organism.
Patients and methods:
Urinary pentosidine in patients with advanced osteoarthritis was measured before and 6 months after total replacement of affected joint. The analyzed samples of cartilage, synovial membrane and affected subchondral bone were taken during installation of total hip or knee endoprosthesis. For pentosidine determination in hydrolysates of body fluids and tissue extracts we elaborated sensitive method based on gradient reversed phase high performance liquid chromatography with fluorescent detection.
Results:
Before the surgery pentosidine in urine of osteoarthritic patients was significantly higher in comparison with levels after the surgery and from the healthy control group. We found positive correlation of pentosidine in urine before and after the surgery and strong correlation of the pentosidine levels in extracts from synovium and affected subchondral bone. In case of urine and cartilage pentosidine significantly increased with age. In joint tissues the highest levels (adjusted to weight of dry mass) were found in synovial membrane extracts (45.00 nmol/g), in cartilage we found 36.28 nmol/g and much lower concentration was in subchondral bone changed by the arthritic process (2.98 nmol/g).
Conclusion:
Significant decrease of pentosidine in urine of patients with advanced osteoarthritis shown repair of the pathological state after total replacement of affected joint. We observed also significant contribution of age to pentosidine accumulation in urine and cartilage. Our results support the hypothesis that pentosidine can play the role of potential biomarker of degradation cartilage breakdown and inflammation in osteoarthritis. Determination of pentosidine could thus contribute to understanding of pathological processes occuring in arthritic joint associated with the presence of local inflammation, excessive glycoxidation loading and ageing of the organism.
Key words:
pentosidine, advanced osteoarthritis, biomarker, connective tissue, high performance liquid chromatography (HPLC)
Sources
1. Lawrence RC, Helmick GG, Arnett DF, et al. Estimates of the prevalence of arthritis and selected musculosceletal disorders in the United States. Arthritis Rheum 1998; 41: 778–788.
2. Sowers M. Epidemiology of risk factors for osteoarthritis: systemic factors. Curr Opin Rheumatol 2001; 13: 447–51.
3. Sharma L. Local factors in osteoarthritis. Curr Opin Rheumatol 2001; 13: 441–6.
4. Zhang W, Doherty M. How important are genetic factors in osteoarthritis? Contributions from family studies. J Rheumatol 2005; 32: 1139–42.
5. Brandt KD. Pathology. In: Brandt KD. Diagnosis and Nonsurgical Management of Osteoarthritis 2003; 43–49.
6. Sell DR, Monnier VM. Structure elucidation of a senescence crosslink from human extracellular matrix. Implication of pentoses in the aging process. J Biol Chem 1989; 264: 21597–602.
7. Cloos PAC, Christgau S. Non-enzymatic covalent modifications of proteins: mechanisms, physiological consequences and clinical applications. Matrix Biol 2002; 21: 39–52.
8. Bailey AJ. Molecular mechanisms of ageing in connective tissues. Mech. Ageing Dev. 2001; 122: 735–755.
9. Maillard LC. Action des acides aminés sur les sucres, formation des mélanoidines par voi e méthodique. C.R. Sc. Acad. Sci 1912; 154: 66–68.
10. Reiser KM. Nonenzymatic glycation of collagen in aging and diabetes. Proc Soc Exp Biol Med 1998; 218: 23–37.
11. Miyata M, Iida Y, Horie K, Cai Z, Sugiyama S, Maeda K. Pathophysiology of advanced glycation end-products in renal failure. Nephrol Dial Transplant 1996; 11: 27–80.
12. Nerlich AG, Schleicher ED. Nε-(carboxymethyl)lysine in atherosclerotic vascular lesions as a marker for local oxidative stress. Atherosclerosis 1999; 144: 41–47.
13. Colaco C, Ledesma MD, Harrington CR, Avila J. The role of the Maillard reaction in other pathologies: Alzheimer’s disease. Nephrol Dial Transplant 1996; 11: 7–12.
14. Goedert M. Parkinson’s disease and other alpha-synucleinopathies. Clin Chem Lab Med 2001; 39: 308–312.
15. Šenolt L, Braun M, Pavelka K. Konečné produkty pokročilé glykace u pacientů s osteoartrózou a revmatoidní artritidou a jejich potenciální úloha v patogenezi těchto onemocnění. Čes. Revmatol 2003; 3: 146–56.
16. Verzijl N, DeGroot J, Oldehinkel E, et al. Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem J 2000; 350: 381–387.
17. Verzijl N, Bank RA, TeKoppele JM, DeGroot J. AGEing and osteoarthritis: a different perspective. Curr Opin Rheumatol 2003; 15: 616–22.
18. Šenolt L, Braun M, Olejárová M, Forejtová Š, Gatterová J, Pavelka K. Increased pentosidine, an Advanced Glycation Endproduct, in serum and synovial fluid from patients with knee osteoarthritis and its relation with cartilage oligomeric matrix protein. Ann Rheum Dis 2005; 64: 886–90.
19. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16(4): 494–502.
20. Špaček P, Adam M. HPLC method for pentosidine determination in urine, serum and tissues as a marker of glycation and oxidation loading of the organism. J Liq Chrom & Rel Technol 2002; 25: 1807–20.
21. Takahashi M, Kushida K, Ohishi T, Kawana K, Hoshino H, Uchiyama A, Inoue T. Quantitative analysis of crosslinks pyridinoline and pentosidine in articular cartilage of patients with bone and joint disorders. Arthritis Rheum 1994; 37: 724–28.
22. Drinda S, Franke S, Canet CC, Petrow P, Bräuer R, Hüttich C, Stein G, Hein G. Identification of the advanced glycation end products Nε-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis. Ann Rheum 2002; 61: 488–92.
23. Pavelka K, Forejtova S, Olejarova M, et al. Hyaluronic acid levels may have predictive value for the progression of knee osteoarthritis. Osteoarthritis Cartilage 2004; 12: 277–83.
24. Hunter DJ, Lavalley M, Li J, et al. Urinary pentosidine does not predict cartilage loss among subjects with symptomatic knee OA: the BOKS Study. Osteoarthritis Cartilage. 2006 Jul 17; [Epub ahead of print]
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2007 Issue 2
Most read in this issue
- Osteonecrosis associated with systemic use of glucocorticoids
- Thrombotic thrombocytopenic purpura in patients with systemic lupus erythematosus
- Recommendations of Czech Rheumatological Society for the treatment of rheumatoid arthritis. Efficacy and treatment strategies
- Imaging methods for evaluation of the structural changes in ankylosing spondylitis